Boston Scientific Adds More Non-Vascular Stents To MedSurg Business With MI Tech Acquisition
Executive Summary
Boston Scientific will pay about $230m for 64% of Korea-based MI Tech, which developed the Hanarostent line of conformable, self-expanding metal stents for endoscopic and urologic applications.
You may also be interested in...
Minute Insight: Boston Scientific Walks Away From MI Tech Deal, Citing Regulatory Hurdles
The Federal Trade Commission said it supports Boston Scientific’s decision to walk away from a planned $230m acquisition of Korea-based MI Tech. Boston Scientific said it could not obtain needed global regulatory approvals.
Boston Scientific Picks Up Pancreatic Stent Maker Xlumena
In the $62.5 million-plus-milestone deal Boston Scientific gets Xlumena's Axios and Hot Axios stent and delivery systems for endoscopic ultrasound-guided transluminal drainage of symptomatic pancreatic pseudocysts. The products fit alongside Boston's Expect endoscopic ultrasound aspiration needles.
News We’re Watching: Two Join Illumina Board, FDA Plans Health Equity Meeting, Pre-Eclampsia Test Cleared
This week, Illumina’s board added two independent members; the VA and the FDA agreed to collaborate on supply chain issues; and Think Surgical, Thermo Fisher Scientific and Blue Earth all landed FDA clearances.